Company

Calithera Biosciences

As of the edition of 20 October 2026, Calithera Biosciences runs 5 drugs; it is on route A at 4 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

Calithera Biosciences was dissolved.

  • Calithera Biosciences, Inc: dissolved

Drugs by status

StatusCount
Active1
Stopped3
Status not established1
Total5

Where it needs a new molecule

Route A at 4 targets, route B at 0 targets.

Three of its 4 rows, by target and route
TargetRoute
IL2RB Interleukin-2 receptor subunit betaRoute A
MTOR Serine/threonine-protein kinase mTORRoute A
SYK Tyrosine-protein kinase SYKRoute A

All 4 rows on route A or B

In the product

4 company-target rows on route A or B; 1 is not shown here, and no score is.

Where its trials are

  • Cancer: 18 trials led
  • Blood and lymph: 8 trials led
  • Immune system: 7 trials led